Betti Marenko and Jilly Traganou, co-editors of “Design in the Pandemic: Dispatches from the Early Months,” use a design perspective to discuss how inventive and localized strategies around the world emerged to handle the challenges posed by COVID-19.
ICI Co-Director Mark Frazier published an article in the International Journal of Asian Studies that discusses the challenges of comparison in China–India urban studies, and [...]
Burcu Kilic, research director for Public Citizen's Access to Medicines Program, discusses the complex web of COVID-19 intellectual property protection, and the new possibilities of emerging manufacturing capacity in the Global South.
K.M. Gopakumar, Senior Research and Legal Advisor at Third World Network, discusses the implications of the new patent vaccine waiver introduced in the WTO and how countries like India face political, technical, and policy constraints in accessing medicine.
Ashok Gurung, prior Senior Director of ICI, was a guest co-editor for the peer-reviewed journal CASTE: A Global Journal on Social Exclusion, in a special issue focused [...]
COVID-19 provides an opportunity to reimagine public health systems to focus on access, writes Andrew McDowell, cultural and medical anthropologist at Tulane University.
Development economist, Jayati Ghosh, explains why more than a third of a million COVID-19 cases are being reported in India daily—and what that says about our world.
In the second interview as part of our new series, "Politics of Vaccine Equity: Conversations on the Frontline," public health consultant and lawyer, Rohit Malpani, discusses how since the HIV/AIDS pandemic there has been from a shift from politics to geopolitics, the new role that emerging economies play in the global landscape of COVID-19 vaccine access, and the importance of technology platforms.
In the first interview as part of our new series, "Politics of Vaccine Equity: Conversations on the Frontline," public health expert and senior policy advisor to the People's Vaccine Alliance, Mohga Kamal-Yanni, discusses how countries are at the whim of Big Pharma for supplying COVID-19 vaccines.
